Alicja Piechocka‐Trocha

7.2k citations
33 papers · 1.7k indexed · h-index 22

Alicja Piechocka‐Trocha

33 papers receiving 1.7k citations

Peers

Alicja Piechocka‐Trocha
Comparison fields: 5 of 80
  • Virology 895
  • Immunology 1.1k
  • Infectious Diseases 419
  • Business and International Management 20
  • Epidemiology 292
Replace Amy E. Baxter with:
Amy E. Baxter United States
Viraj Kulkarni United States
Adam J. Fletcher United Kingdom
Fengwen Xu China
Laura E. McCoy United Kingdom
Christian L. Boutwell United States
María Salgado Spain
Xavier Lahaye France
Jonathan Richard Canada
Bader Yassine‐Diab Canada
Alicja Piechocka‐Trocha relative to Amy E. Baxter United States Amy E. Baxter's profile →
Citations per field
00.5×2.5×
Amy E. Baxter · 1×
Citations per year

Countries citing papers authored by Alicja Piechocka‐Trocha

Since Specialization
Citations

This map shows the geographic impact of Alicja Piechocka‐Trocha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alicja Piechocka‐Trocha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alicja Piechocka‐Trocha more than expected).

Fields of papers citing papers by Alicja Piechocka‐Trocha

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alicja Piechocka‐Trocha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alicja Piechocka‐Trocha. The network helps show where Alicja Piechocka‐Trocha may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Alicja Piechocka‐Trocha, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alicja Piechocka‐Trocha Line = papers co-authored together Alicja Piechocka‐Trocha links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20251
2 20241
3 202210
4 202229
5 202153
6 201992
7 20174
8 2016235
9 20165
10 2016103
11 20151
12 20145
13 201256
14 201254
15 2011123
16 201168
17 201014
18 201086
19 200972
20 20091

About Alicja Piechocka‐Trocha

Alicja Piechocka‐Trocha is a scholar working on Virology, Immunology and Infectious Diseases, having authored 33 papers that have together received 1.7k indexed citations. Recurring topics across this work include HIV Research and Treatment (25 papers), Immune Cell Function and Interaction (24 papers), T-cell and B-cell Immunology (12 papers), vaccines and immunoinformatics approaches (5 papers), HIV/AIDS Research and Interventions (4 papers), SARS-CoV-2 and COVID-19 Research (3 papers), Immunotherapy and Immune Responses (3 papers) and Cytomegalovirus and herpesvirus research (3 papers). The work is most often cited by research in Virology (895 citations), Immunology (1.1k citations) and Infectious Diseases (419 citations). Alicja Piechocka‐Trocha has collaborated with scholars based in United States, South Africa and United Kingdom. Frequent co-authors include Bruce D. Walker, Florencia Pereyra, Marcus Altfeld, Mary Carrington, Boris Jülg, Wilfredo F. García-Beltrán, Marylyn M. Addo, Huabiao Chen, Ryan J. Park and Hendrik Streeck.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026